作者
Romy E van Weelderen, Christine J Harrison, Kim Klein, Yilin Jiang, Jonas Abrahamsson, Todd Alonzo, Richard Aplenc, Nira Arad-Cohen, Emmanuelle Bart-Delabesse, Barbara Buldini, Barbara De Moerloose, Michael N Dworzak, Sarah Elitzur, José M Fernández Navarro, Alan Gamis, Robert B Gerbing, Bianca F Goemans, Hester A de Groot-Kruseman, Erin Guest, Shau-Yin Ha, Henrik Hasle, Charikleia Kelaidi, Hélène Lapillonne, Guy Leverger, Franco Locatelli, Takako Miyamura, Ulrika Norén-Nyström, Sophia Polychronopoulou, Mareike Rasche, Jeffrey E Rubnitz, Jan Stary, Anne Tierens, Daisuke Tomizawa, C Michel Zwaan, Gertjan JL Kaspers
发表日期
2024/6/25
期刊
Blood Advances
卷号
8
期号
12
页码范围
3200-3213
出版商
American Society of Hematology
简介
Abstract
A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1256 children with KMT2A-r AML aims to validate the prognostic value of established recurring KMT2A fusions and additional cytogenetic aberrations (ACAs) and to define additional, recurring KMT2A fusions and ACAs, evaluating their prognostic relevance. Compared with our previous study, 3 additional, recurring KMT2A-r groups were defined: Xq24/KMT2A::SEPT6, 1p32/KMT2A::EPS15, and 17q12/t(11;17)(q23;q12). Across 13 KMT2A-r groups, 5-year event-free survival probabilities varied significantly (21.8%-76.2%; P < .01). ACAs occurred in 46.8% of 1200 patients with complete karyotypes, correlating with inferior overall survival …
引用总数
20242
学术搜索中的文章
RE van Weelderen, CJ Harrison, K Klein, Y Jiang… - Blood Advances, 2024